|Bid||0.0000 x 900|
|Ask||0.0000 x 3200|
|Day's Range||1.6400 - 1.6800|
|52 Week Range||0.8040 - 3.6800|
|Beta (5Y Monthly)||2.26|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 15, 2021 - Nov 19, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.75|
Subscribe to Yahoo Finance Plus to view Fair Value for TENXLearn more
MORRISVILLE, N.C., October 06, 2021--Tenax Therapeutics, Inc. today announced that the FDA has reviewed and cleared its Investigational New Drug (IND) application for imatinib.
MORRISVILLE, N.C., September 28, 2021--Tenax Therapeutics will present a company overview at the virtual Benziga Healthcare Small Cap Conference being held from September 29-30, 2021.
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Second Quarter 2021 Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported second quarter 2021 results via the issuance of a press release and the filing of Form 10-Q to the SEC on August 16, 2021. Highlights for the second quarter and to-date: ➢ Publication of HELP trial results - April 2021 ➢